<DOC>
	<DOCNO>NCT01985555</DOCNO>
	<brief_summary>The purpose study evaluate safety tolerability single multiple dos volitinib administer patient locally advance metastatic solid tumor determine MTD ( Maximum Tolerated Dose ) RPTD ( recommend Phase 2 dose ) .</brief_summary>
	<brief_title>Phase I Study Volitinib ( HMPL-504 ) Patients With Advanced Solid Tumors</brief_title>
	<detailed_description>The primary endpoint evaluation safety tolerability study therapy follow initiation multiple dose HMPL-504 . The safety tolerability variable evaluate study adverse event , physical examination , vital sign ( specifically include blood pressure ) , clinical laboratory evaluation include serum chemistry , hematology ( Maximum Tolerated Dose ) , urinalysis ( detailed sediment analysis , proteinuria , 24-hour urine collection protein ) , electrocardiogram ( ECGs ) triplicate , Incidence nature DLTs ( Dose-Limiting Toxicity ) , determine MTD ( Maximum Tolerated Dose ) .</detailed_description>
	<criteria>Signed Informed Consent Form Age≥18 year Histologically cytologically document ( include dose escalation stage dose expansion stage ) , incurable , locally advanced , metastatic solid malignancy In dose escalation stage : patient malignant solid tumor type standard therapy either proven ineffective ( progress , fail respond ) intolerable , access standard systemic therapy standard systemic therapy exist . In dose expansion stage : Metastatic locally advance gastric cancer patient cMet positive b ) Metastatic locally advance EGFR wild type NSCLC patient cMet positive . ECOG performance status 0 , 1 Male female patient childproducing potential must agree use double barrier contraception , condom , sponge , foam , jelly , diaphragm intrauterine device ( IUD ) , contraceptive ( oral parenteral ) , Implanon , injectables avoidance pregnancy measure study 90 day last day treatment Absolute neutrophil count ＜1500 cells/uL , hemoglobin ＜9 g/dL platelet count &lt; 100,000/mm3 Total bilirubin &gt; 1.5×the upper limit normal ( ULN ) . Herbal therapy &lt; 1 week prior Day 1 Adverse event prior anticancer therapy resolve Grade ≤ 1 , except alopecia Clinical significant active infection Known clinically significant history liver disease , include viral hepatitis , current alcohol abuse , cirrhosis Known human immunodeficiency virus infection Pregnant ( positive pregnancy test ) lactate woman Inability take oral medication , prior surgical procedure affect absorption , active peptic ulcer disease Involved clinical trial &lt; 4weeks prior Day 1 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Phase I</keyword>
	<keyword>Safety</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>